Table 3.
Univariate and multivariate models of ORR for patients categorized according to their mutations (N = 76 (measured in 76 patients who had detectable gene mutations))
| Univariate models | Multivariate models | |||
|---|---|---|---|---|
| OR (95% Cl) | P value | OR (95% Cl) | P value | |
| Category | ||||
| Other mutations | 1.0 | 1.0 | ||
| Mutations in panel ET# | 3.73 (1.43, 9.73) | 0.0070 | 4.45 (1.46, 13.50) | 0.0085 |
| Age | 1.03 (0.99, 1.07) | 0.0920 | 1.04 (0.99, 1.08) | 0.1351 |
| Sex | ||||
| Male | 1.0 | 1.0 | ||
| Female | 0.43 (0.17, 1.11) | 0.0823 | 0.39 (0.13, 1.21) | 0.1035 |
| BM blasts | 0.13 (0.02, 0.80) | 0.0275 | 0.32 (0.04, 3.01) | 0.3218 |
| HB | 1.02 (1.00, 1.04) | 0.0244 | 1.01 (0.99, 1.04) | 0.2979 |
| WBC | 1.00 (0.98, 1.03) | 0.9117 | ||
| PLT | 1.01 (1.00, 1.01) | 0.1566 | ||
| ECOG PS | ||||
| 0 | 1.0 | |||
| 1 | 0.24 (0.08, 0.78) | 0.0169 | ||
| 2 | 0.73 (0.19, 2.90) | 0.6580 | ||
| 3 | 0.00 (0.00, Inf) | 0.9913 | ||
| Diagnosis | ||||
| Refractory | 1.0 | 1.0 | ||
| Early relapse | 2.00 (0.69, 5.78) | 0.2002 | 1.81 (0.51, 6.47) | 0.3600 |
| Late relapse | 4.27 (1.09, 16.83) | 0.0377 | 4.91 (0.90, 26.80) | 0.0663 |
| Prior therapies | ||||
| 0–5 | 1.0 | |||
| 6–10 | 1.32 (0.48, 3.66) | 0.5912 | ||
| ≥ 11 | 1.87 (0.49, 7.18) | 0.3588 | ||
Abbreviations: OR odds ratio, CI confidence interval, BM bone marrow, HB hemoglobin, WBC white blood cell count, PLT platelets, ECOG PS Eastern Cooperative Oncology Group performance score
#Panel ET: epigenetic modifier-related or transcription factor-related gene mutations, but without FLT3-ITD co-mutation